Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%

BACKGROUND: For patients with advanced non-small-cell lung cancer (NSCLC) and high (⩾50%) programmed cell death-ligand 1 (PD-L1) expression, effective first-line immune-oncology monotherapies with significant survival benefits are approved, cemiplimab being the most recent. In a phase III trial, cem...

Descripción completa

Detalles Bibliográficos
Autores principales: Freemantle, Nick, Xu, Yingxin, Wilson, Florence R., Guyot, Patricia, Chen, Chieh-I, Keeping, Sam, Konidaris, Gerasimos, Chan, Keith, Kuznik, Andreas, Atsou, Kokuvi, Glowienka, Emily, Pouliot, Jean-Francois, Gullo, Giuseppe, Rietschel, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210099/
https://www.ncbi.nlm.nih.gov/pubmed/35747163
http://dx.doi.org/10.1177/17588359221105024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210099/
https://www.ncbi.nlm.nih.gov/pubmed/35747163
http://dx.doi.org/10.1177/17588359221105024

Ejemplares similares